Stockscreener 앱 받기
31.87
1.82%
-0.59
시간 외 거래:
31.87
Ultragenyx Pharmaceutical Inc 주식(RARE)의 최신 뉴스
Ultragenyx (RARE) Earnings Call Highlights Growth and Challenges - TipRanks
Ultragenyx Pharmaceutical (NASDAQ:RARE) Posts Earnings Results - MarketBeat
Will Ultragenyx Pharmaceutical Inc. (UP0) stock issue positive guidance2025 Key Lessons & Proven Capital Preservation Tips - fcp.pa.gov.br
TD Cowen Updates Ultragenyx Pharmaceutical (RARE) Price Target | - GuruFocus
Can Ultragenyx Pharmaceutical Inc. (UP0) stock surprise with quarterly resultsJuly 2025 Snapshot & Daily Profit Maximizing Tips - newser.com
Truist Securities Lowers Price Target for Ultragenyx Pharmaceuti - GuruFocus
Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y - TradingView
RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $72 From $77, Maintains Outperform Rating - MarketScreener
Ultragenyx outlines 14%–20% 2025 revenue growth, advances late-stage pipeline with $400M OMERS financing - MSN
Ultragenyx Pharmaceutical Inc. SEC 10-Q Report - TradingView
Ultragenyx Pharmaceutical Q3 2025 Earnings Call Transcript - MarketBeat
Can Ultragenyx Pharmaceutical Inc. stock sustain revenue growthJuly 2025 Volume & Fast Gain Swing Trade Alerts - newser.com
Why Ultragenyx Pharmaceutical Inc. stock appeals to dividend seekersJuly 2025 Levels & Smart Allocation Stock Tips - newser.com
Ultragenyx: Q3 Earnings Snapshot - CT Insider
Why Ultragenyx Pharmaceutical Inc. stock remains on watchlistsGap Up & Stepwise Trade Execution Plans - newser.com
Ultragenyx Pharmaceutical Q3 Net Loss Widens, Revenue Increases - MarketScreener
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is it too late to sell Ultragenyx Pharmaceutical Inc.July 2025 Chart Watch & Advanced Technical Analysis Signals - newser.com
Key metrics from Ultragenyx Pharmaceutical Inc.’s quarterly dataWeekly Trade Summary & AI Enhanced Trading Signals - newser.com
What hedge fund moves indicate for Ultragenyx Pharmaceutical Inc. (UP0) stock2025 Historical Comparison & AI Enhanced Trading Signals - newser.com
Will Ultragenyx Pharmaceutical Inc. stock remain a Wall Street favorite2025 Analyst Calls & Real-Time Chart Breakout Alerts - newser.com
Will Ultragenyx Pharmaceutical Inc. see short term momentumJuly 2025 Rallies & Stepwise Trade Signal Implementation - newser.com
Ultragenyx Pharmaceutical Inc (RARE) Q3 2025 Earnings Call Highl - GuruFocus
Can Ultragenyx Pharmaceutical Inc. stock weather global recessionMarket Growth Summary & Stock Portfolio Risk Management - newser.com
Ultragenyx Reports Q3 2025 Financial Results - TipRanks
Is Ultragenyx Pharmaceutical Inc. stock attractive after correction2025 Historical Comparison & Accurate Intraday Trade Tips - newser.com
Ultragenyx Reports Growth And Wall Street Sees More Ahead - Finimize
Ultragenyx (RARE) Secures $400M Through Expanded Royalty Deal wi - GuruFocus
Ultragenyx tumbles on $400 mln Crysvita royalty sale - TradingView
Here's What Key Metrics Tell Us About Ultragenyx (RARE) Q3 Earnings - Nasdaq
Ultragenyx shares tumble as third quarter earnings fall short of expectations - Investing.com UK
Ultragenyx shares tumble as third quarter earnings fall short of expectations By Investing.com - Investing.com South Africa
Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Ultragenyx sells some royalties on Crysvita to OMERS Life Sciences - Seeking Alpha
Ultragenyx (RARE) Maintains 2025 Financial Guidance and Projects Profitability in 2027 - GuruFocus
Ultragenyx Pharmaceutical Inc Reports Q3 2025 Earnings: EPS of - GuruFocus
RARE's Q3 Revenue Misses Estimates Amid Strategic Advancements - GuruFocus
Ultragenyx Signs $400M Royalty Purchase Agreement - TipRanks
Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update - The Manila Times
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences - The Manila Times
Ultragenyx (NASDAQ: RARE) sells Crysvita royalties to OMERS for $400M, capped at 1.55x - Stock Titan
Published on: 2025-11-04 05:38:55 - newser.com
Is Ultragenyx Pharmaceutical Inc. stock attractive for long term wealth buildingQuarterly Earnings Summary & Weekly Watchlist for Hot Stocks - newser.com
Will Ultragenyx Pharmaceutical Inc. (UP0) stock hit Wall Street targetsJuly 2025 Technicals & Real-Time Volume Analysis Alerts - newser.com
Can Ultragenyx Pharmaceutical Inc. rally from current levelsM&A Rumor & Safe Entry Trade Reports - newser.com
Published on: 2025-11-04 02:37:03 - newser.com
Published on: 2025-11-04 01:40:43 - newser.com
Is Ultragenyx Pharmaceutical Inc. stock dividend yield sustainableStock Surge & AI Based Buy and Sell Signals - newser.com
Dosing begins in broader trial of Angelman syndrome therapy - Angelman Syndrome News
6.82%
1.34%
자본화:
|
볼륨(24시간):